DR. BRUCE N CRONSTEIN, MD
Osteopathic Medicine at 1 Ave, New York, NY

6555545, Apr 29, 2003

Feb 12, 2001

09/780365

Bruce N. Cronstein - New York NY
Edwin Chan - New York NY

New York University - New York NY

A61K 31519

514261, 514 46, 514258, 514262, 514263, 514266, 544242, 544239, 544253, 544256, 544262, 544264, 544265, 536 2613

Hepatic cirrhosis and fibrosis and fatty liver can be prevented and treated by administering to a subject in need thereof an effective amount of at least one adenosine A receptor antagonist or at least one adenosine uptake promotor.

8183225, May 22, 2012

Nov 10, 2008

12/291510

Bruce N. Cronstein - New York NY, US
Zhong Sheng Peng - New York NY, US

New York University - New York NY

A01N 43/04, C07H 19/16, A61K 31/52, C07K 14/705

514 46, 536 273

The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine Areceptor, in particular, an agonist of an adenosine Areceptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine Aagonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an Aagonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.

2012028, Nov 8, 2012

May 18, 2012

13/475067

Bruce N. Cronstein - New York NY, US
Aranzazu Mediero Munoz - New York NY, US

A61K 31/7076, A61P 19/00

514 45

The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine Areceptor, in particular, an agonist of an adenosine Areceptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine Aagonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an Aagonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.

6313091, Nov 6, 2001

May 20, 1998

9/000179

Hans-Georg Wisniewski - New York NY
Jan Vilcek - New York NY
Bruce Cronstein - New York NY

New York University - New York NY

A61K 3800, C07K 1400, C07H 2102, A01N 3718, C12P 2106

514 12

Pleiotropic pro-inflammatory cytokines, such as TNF and IL-1, induce expression of a protein molecule, termed TSG-6, in connective tissue cells. TSG-6, or pharmaceutical compositions containing TSG-6, can be used to treat inflammatory diseases and disorders and cancer-related pathologies. Inflammatory diseases and disorders, or cancer related pathologies, can also be treated by introducing human cells transfected with a DNA molecule containing a DNA segment encoding TSG-6 protein, into humans to express therapeutically effective amounts of TSG-6 in vivo or by introducing a vector carrying a DNA segment encoding TSG-6 protein directly into humans in vivo.

7795427, Sep 14, 2010

Feb 13, 2007

11/705689

Bruce N. Cronstein - New York NY, US
Firas Mohamed Kara - Woodside NY, US

New York University - New York NY

C07D 473/00

544267, 424 92

The invention provides methods and compositions for modulating osteoclastogenesis and for treating bone diseases characterized by bone loss or a decrease in bone mass or density, by administering a compound or agent that modulates the adenosine A1 receptor, in particular, an inhibitor or antagonist of the A1 receptor.

2009020, Aug 20, 2009

Oct 24, 2008

12/290021

Bruce N. Cronstein - New York NY, US
Zhong Sheng Peng - New York NY, US

A61K 9/00, A61K 31/522, A61K 38/16, A61K 38/02, A61K 31/7052, A61K 39/395, A61K 31/7076, A61P 1/16

424422, 51426334, 514 12, 514 2, 514 44 R, 4241721, 514 45

The invention provides methods and compositions for treating a hepatic disease, for reducing fat deposition in the liver and for inhibiting fibrosis of the liver by administering a compound or agent that modulates an adenosine receptor, in particular, an inhibitor or antagonist of an adenosine receptor, especially an Aor Aadenosine receptor antagonist.

5932558, Aug 3, 1999

Sep 13, 1996

8/712942

Bruce N. Cronstein - New York NY
Richard I. Levin - New York NY

New York University - New York NY

A61K 3170

514 46

Agonists of the adenosine A. sub. 2 receptor promote the migration of endothelial cells, fibroblasts and epithelial cells. Thus, methods and pharmaceutical compositions useful for treating wounds and promoting wound healing comprise agents which cause stimulation of the adenosine A. sub. 2 receptor, preferably receptor agonists and adenosine uptake blockers. Preferred agonists include 2-phenylaminoadenosine, 2-para-2-carboxyethylphenyl-amino-5'N-ethylcarboxamidoadenosine, 5'N-ethylcarbox-amidoadenosine, 5'N-cyclopropyladenosine, 5'N-methyl-carboxamidoadenosine and PD-125944. Preferred uptake blockers include dipyridamole, nitrobenzylthio-inosine, dilazep and R75231.